Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 2/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26461597 | 0.63 | SCN5A (0.57) | — | |
| SCHEMBL23088083 | 0.62 | POLB (0.41) | MEN1KMT2AALDH1A1MAPK1NPC1 | |
| SCHEMBL26462791 | 0.62 | SCN5A (0.44) | MEN1KMT2AALDH1A1MAPK1NPC1 | |
| SCHEMBL25208215 | 0.60 | LRRK2 (0.33) | MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL14776331 | 0.59 | POLB (0.36) | MEN1KMT2AALDH1A1MAPK1POLB | |
| SCHEMBL26459298 | 0.53 | KMT2A (0.53) | MEN1KMT2AALDH1A1MAPK1NPC1 | |
| SCHEMBL28041698 | 0.53 | POLB (0.54) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL20208532 | 0.51 | SCN5A (0.54) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL21863408 | 0.51 | POLB (0.69) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL5100079 | 0.51 | POLB (0.47) | MEN1KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | MEN1 1636/4885KMT2A 1572/4885ALDH1A1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.